FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement regarding the Breakthrough Therapy Designation Granted to Pharmaceutical Product of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
21 April 2023

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196 Stock abbreviation: Fosun Pharma No: Lin 2023-054

Bond code: 143422 Bond abbreviation: 18 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement regarding the Breakthrough Therapy Designation Granted to Pharmaceutical Product of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

According to the public announcement made by the Centre for Drug Evaluation of National Medical Products Administration (the "**NMPA**"), the FCN-159 tablets (the "**Investigational New Drug**") of Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) ("**Fosun Pharmaceutical Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the "**Company**" and, together with its subsidiaries/units, the "**Group**", the same applies below), have been granted breakthrough therapy designation for the treatment of histiocytic tumors.

II. Basic Information and Research Progress of the Investigational New Drug

The Investigational New Drug is an innovative small molecule chemical drug self-developed by the Group , which is a MEK1/2 selective inhibitor and is intended to be used primarily for the treatment of advanced solid tumors, type I neurofibromas, histiocytic tumors and arteriovenous malformations.

As at the date of this announcement, the Investigational New Drug is at the stage of Phase I clinical trial in China (excluding Hong Kong, Macau and Taiwan region for the purpose of this announcement, the same applies below) for the treatment of malignant melanoma; the Investigational New Drug is at the stage of Phase II clinical trials in China, the United States and Europe for the treatment of type I neurofibroma; and the Investigational New Drug is at the stage of Phase II clinical trials in China for the treatment of histiocytic tumors, low-grade glioma and arteriovenous malformations respectively. The application for Phase II clinical trial of the Investigational New Drug for childhood Langerhans cell histiocytosis/Langerhans cell histiocytic hyperplasia has also been approved by the NMPA.

As at the date of this announcement, the MEK1/2 selective inhibitor approved for launch in China include MEGININE (邁吉寧®) (Trametinib Tablets) of Novartis Europharm Limited. According to the data from IQVIA CHPA (provided by IQVIA, a professional information and strategic consulting service provider for the pharmaceutical and health industry, IQVIA CHPA data represents the drug sales market of hospitals with over 100 beds in China. The actual sales of different drugs may differ from the IQVIA CHPA data to varying degrees due to their different sales distribution channels), the sales of MEK1/2 selective inhibitor in China amounted to approximately RMB98.68 million in 2022.

As of March 2023, the Group has invested approximately RMB 311.95 million (unaudited) in total in the research and development ("**R&D**") of the Investigational New Drug at this stage.

III. Risk Reminder

As required by the relevant laws and regulations in China, the Investigational New Drug is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of new drugs is a long-term task involving various

uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

21 April 2023

* For identification purpose only